宫颈癌患者外周血ERCC1基因多态性对顺铂新辅助化疗疗效的影响  

Influence of Peripheral Blood ERCC1 Gere Polymorphism on Patients with Cervical Cancer Undergoing Neoadjuvant Cisplatin Chemotherapy

作　　者：关灵[1] 郑锐年[1] 吴少敏[1] 林顺欢[1] 李仲均[1] 吴依芬[1] 廖玉婷[1] 江丽华[1] 赵燕海[1] 

机构地区：[1]广东省东莞市人民医院,广东东莞523000

出　　处：《中国药业》2016年第9期15-18,共4页China Pharmaceuticals

基　　金：广东省东莞市科技计划医疗卫生类科研一般项目;项目编号:2015105101180

摘　　要：目的探讨宫颈癌患者外周血核苷酸切除修复交叉互补1(ERCC1)基因多态性对顺铂新辅助化学治疗(简称化疗)疗效的影响。方法选择2010年3月至2014年6月医院收治的宫颈癌患者80例,根据外周血ERCC1基因表达的不同分为CC组和TT组,各40例。两组患者均给予紫杉醇联合顺铂化疗,21 d为1个周期,共治疗6个周期。治疗结束时比较两组患者的近期疗效、中位生存期、中位进展时间、2年生存率,记录不良反应的发生情况。结果治疗后,TT组近期疗效52.50%,CC组近期疗效为67.50%,CC组显著优于对照组,差异有统计学意义(P<0.05);CC组患者的中位进展时间、中位生存期以及2年生存率均显著高于TT组,差异均具有统计学意义(P<0.05)。治疗后,两组患者血清中CYFRA21-1及SCC-Ag表达均较治疗前有所下降,且CC组下降程度优于TT组,差异均具有统计学意义(P<0.05)。两组患者各方面不良反应发生率结果均无显著性差异(P>0.05)。结论 ERCC1 C19007T表达为C/C型的患者相比较表达为T/T型的患者临床疗效更好,其中位进展时间、中位生存期均较长,2年生存率较高,化疗后血清中特异肿瘤标志物的表达可显著降低,且不良反应发生率相当。Objective To investigate the influence of peripheral blood ERCC1 gene polymorphism on patients with cervical cancer undergoing neoadjuvant cisplatin chemotherapy. M ethods 80 cases with cervical cancer from March 2010 to June 2014 were divided into CC group and TT group according to the ERCC1 gene expression of the peripheral blood, 40 cases in each group. The two groups were given paclitaxel combined with cisplatin chemotherapy, 21 d for 1 course, altogether 6 courses. At the end of the treatment, the short-term efficacy of the two groups were compared, and the median survival, the median time to progression, the two years survival rate were compared between the two groups, and the occurrence of adverse reactions was recorded. Results After treatment, the short- term efficacy of the TT group was 52. 50%, the short- term efficacy of CC group was 67. 50%, CC group was significantly better than that in control group（ P〈0. 05）; the median progression, median survival and 2- year survival rate were significantly higher than those in TT group（ P〈0. 05）. After treatment, serum CYFRA21- 1, SCC- Ag expressions in the two groups were decreased, and the level of CC was significantly higher than that of TT group, the difference was statistically significant（ P〈0. 05）. The incidence of adverse reactions in two groups were observed, and the results showed no significant difference（ P〉0. 05）. Conclusion The clinical efficacy of C19007 T ERCC1 in patients with C/C was better than that of patients with T/T. The median time to progression, median survival and two years survival were higher. The expression of specific tumor markers in serum was significantly lower, and the incidence rate of adverse reactions was similar.

关 键 词：核苷酸切除修复交叉互补1 C19007T 基因多态性 宫颈癌 临床疗效 

分 类 号：R979.1[医药卫生—药品] Q786[医药卫生—药学]